# Marco Calabr

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 26 papers | 274 citations | 11 h-index | 15 g-index |
| 29 ext. papers | 334 ext. citations | 4 avg, IF | 2.73 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 26 | Possible Modulatory Role of ARC Gene Variants in Mood Disorders. *Clinical Psychopharmacology and Neuroscience*, **2021**, 19, 46-52 | 3.4 | 2 |
| 25 | Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. *Current Medicinal Chemistry*, **2021**, 28, 4296-4320 | 4.3 | 1 |
| 24 | Genetic variants associated with psychotic symptoms across psychiatric disorders. *Neuroscience Letters*, **2020**, 720, 134754 | 3.3 | 4 |
| 23 | Gene Variants Have a Cross-diagnostic Influence on Psychosis and Treatment Improvement in Mood Disorders. *Clinical Psychopharmacology and Neuroscience*, **2020**, 18, 231-240 | 3.4 | 4 |
| 22 | Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer\'s disease. *Molecular Biology Reports*, **2020**, 47, 191-200 | 2.8 | 3 |
| 21 | Alzheimer\'s Disease and Neurotransmission Gene Variants: Focus on Their Effects on Psychiatric Comorbidities and Inflammatory Parameters. *Neuropsychobiology*, **2019**, 78, 79-85 | 4 | 6 |
| 20 | FKBP5 Gene Variants May Modulate Depressive Features in Bipolar Disorder. *Neuropsychobiology*, **2019**, 78, 104-112 | 4 | 0 |
| 19 | Genes Involved in Neurodevelopment, Neuroplasticity and Major Depression: No Association for and. *Clinical Psychopharmacology and Neuroscience*, **2019**, 17, 364-368 | 3.4 | 8 |
| 18 | Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features. *Journal of Molecular Neuroscience*, **2018**, 64, 62-74 | 3.3 | 3 |
| 17 | The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. *Human Psychopharmacology*, **2018**, 33, e2682 | 2.3 | 6 |
| 16 | Neuroplasticity, Neurotransmission and Brain-Related Genes in Major Depression and Bipolar Disorder: Focus on Treatment Outcomes in an Asiatic Sample. *Advances in Therapy*, **2018**, 35, 1656-1670 | 4.1 | 9 |
| 15 | Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. *European Archives of Psychiatry and Clinical Neuroscience*, **2017**, 267, 723-735 | 5.1 | 14 |
| 14 | Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples. *Advances in Therapy*, **2017**, 34, 1482-1497 | 4.1 | 3 |
| 13 | Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. *PLoS ONE*, **2017**, 12, e0187034 | 3.7 | 14 |
| 12 | Progress and prospects in pharmacogenetics of antidepressant drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 1157-68 | 5.5 | 22 |
| 11 | The microtubule-associated molecular pathways may be genetically disrupted in patients with Bipolar Disorder. Insights from the molecular cascades. *Journal of Affective Disorders*, **2016**, 190, 429-438 | 6.6 | 10 |
| 10 | Genes Involved in Neurodevelopment, Neuroplasticity, and Bipolar Disorder: CACNA1C, CHRNA1, and MAPK1. *Neuropsychobiology*, **2016**, 74, 159-168 | 4 | 14 |

| | | | |
|---|---|---|---|
| 9 | Possible biomarkers modulating haloperidol efficacy and/or tolerability. *Pharmacogenomics*, **2016**, 17, 507-29 | 2.6 | |
| 8 | Role of neurodevelopment involved genes in psychiatric comorbidities and modulation of inflammatory processes in Alzheimer\'s disease. *Journal of the Neurological Sciences*, **2016**, 370, 162-166 | 3.2 | 7 |
| 7 | CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. *Pharmacogenomics*, **2015**, 16, 689-701 | 2.6 | 19 |
| 6 | Genes involved in pruning and inflammation are enriched in a large mega-sample of patients affected by Schizophrenia and Bipolar Disorder and controls. *Psychiatry Research*, **2015**, 228, 945-9 | 9.9 | 19 |
| 5 | Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. *Journal of Affective Disorders*, **2015**, 179, 88-94 | 6.6 | 29 |
| 4 | A molecular pathway analysis informs the genetic background at risk for schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2015**, 59, 21-30 | 5.5 | 14 |
| 3 | Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2013**, 44, 271-8 | 5.5 | 35 |
| 2 | FMO3 allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor. *Gene*, **2013**, 515, 410-5 | 3.8 | 16 |
| 1 | Identification of a novel CCM2 gene mutation in an Italian family with multiple cerebral cavernous malformations and epilepsy: a causative mutation?. *Gene*, **2013**, 519, 202-7 | 3.8 | 12 |